Juvena Therapeutics

Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases.

We are achieving this through a fully integrated, end-to-end artificial intelligence-enabled platform that combines a diverse protein library, in silico mapping of secreted proteins to specific disease phenotypes, in vitro human cell screening, in vivo pharmacology, and protein engineering capabilities.

Juvena has developed new tools to overcome translational barriers and pioneer treatments like our first-in-class myotonic dystrophy program. We partnered with the Myotonic Dystrophy Foundation to deliver transformative outcomes for patients.

Myotonic Dystrophy Type 1 is a genetic disorder causing progressive muscle degeneration and metabolic impairments. It impacts skeletal muscle and frequently disrupts cardiac conduction, respiration, swallowing, and cognitive function.

Additional metabolic diseases Juvena focuses on include obesity, sarcopenia, lung and liver diseases.